The TRICORDER trial tested the implementation of an artificial intelligence (AI) stethoscope in routine primary care in the UK for the detection of three cardiovascular diseases: heart failure, atrial fibrillation and valvular heart disease (VHD). This was a cluster-randomized controlled implementation trial with a pragmatic design that generated real-world data to understand barriers to implementing innovations in healthcare. AI stethoscope implementation did not significantly increase heart failure detection or community diagnosis after 12 months. However, AI stethoscope use was independently associated with significantly higher detection rates of heart failure, atrial fibrillation, and VHD. The study included more than 12,000 patients from 96 practices with an AI stethoscope versus 109 practices without the technology. Heart failure was detected more than twice as often, rhythm disorders more than three-and-a-half times more often, and heart valve disease almost twice as often compared to a regular stethoscope.[1][2][3][4] An AI stethoscope captures subtle differences in heartbeat and blood flow with a microphone, records an EKG, and analyzes the data with an AI trained on tens of thousands of recordings.[1][2]